Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high ...

Moderna has received nearly $2.5 billion from U.S. taxpayers to develop, manufacture and distribute its vaccine; while Pfizer/BioNTech has been promised just under $2 billion for manufacturing and ...

Moderna, a Cambridge, Massachusetts-based biotechnology company, developed a COVID-19 vaccine, mRNA-1273, that was authorized Friday. How effective are the candidate vaccines, and what does that mean?

Moderna, the maker of one of three COVID-19 vaccines currently authorized for use in the U.S., announced Tuesday it will start testing its vaccine on children as young as 6 months old.. The move ...